Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
Clinical trial NCT00452140 · TERMINATED
Trial details
- NCT number
- NCT00452140
- Sponsor
- Neovii Biotech
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-03-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.